This study found there was high certainty for patients with asthma between 6-12 years old that used omalizumab to experience decreased annual exacerbation rate, improved quality of life (QoL), and reduced ICS and rescue medication use.
Researchers conducted systemic reviews assessing the efficacy and safety of omalizumab, benralizumab, and dupilumab versus standard care for patients with uncontrolled severe allergic asthma. The researchers assessed certainty of evidence using GRADE. For annualized asthma exacerbation all three biological reduced the rate with high certainty. Benralizumab and dupilumab improved asthma control with high certainty while omalizumab improved it with moderate certainty. However, none of the improvement for asthma control reached the minimal important difference (MID). Both benralizumab and omalizumab improved QoL with high certainty, and omalizumab reached the MID. Benralizumab and omalizumab demonstrated an increase in drug-related adverse events with low to moderate certainty. All three biologicals had moderate certainty for an ICER/QALY value above the willingness to pay threshold. Omalizumab enabled ICS dose reduction with high certainty.